CERT
Overvalued by 19.5% based on the discounted cash flow analysis.
Market cap | $2.10 Billion |
---|---|
Enterprise Value | $2.32 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-0.08 |
Beta | 1.45 |
Outstanding Shares | 160,916,057 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 263.52 |
---|---|
PEG | -312.42 |
Price to Sales | 6.54 |
Price to Book Ratio | 2.18 |
Enterprise Value to Revenue | 5.71 |
Enterprise Value to EBIT | 208.11 |
Enterprise Value to Net Income | 290 |
Total Debt to Enterprise | 0.16 |
Debt to Equity | 0.35 |
No data
No data
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the ...